Janus Henderson Global Life Sciences Fund Class D (JNGLX)
| Fund Assets | 5.40B |
| Expense Ratio | 0.80% |
| Min. Investment | $2,500 |
| Turnover | 30.00% |
| Dividend (ttm) | 3.70 |
| Dividend Yield | 4.48% |
| Dividend Growth | -6.73% |
| Payout Frequency | Annual |
| Ex-Dividend Date | Dec 5, 2025 |
| Previous Close | 82.41 |
| YTD Return | 2.85% |
| 1-Year Return | 21.90% |
| 5-Year Return | 49.25% |
| 52-Week Low | 58.98 |
| 52-Week High | 83.50 |
| Beta (5Y) | n/a |
| Holdings | 104 |
| Inception Date | Dec 31, 1998 |
About JNGLX
Janus Henderson Global Life Sciences Fund Class D is an open-end mutual fund that targets long-term capital growth by investing primarily in equities of companies within the global life sciences sector. The fund focuses on a diverse range of healthcare segments, including pharmaceuticals, biotechnology, medical devices, and healthcare services, seeking firms that address unmet medical needs or contribute to healthcare efficiency. Its investment approach is global and diversified, spanning companies of varying market capitalizations and geographies, with at least 80% of assets invested in life sciences-oriented companies and up to 20% in developing markets. The fund employs fundamental, bottom-up analysis to identify growth opportunities and benchmarks its performance against the MSCI World Health Care Index and the S&P 500 Index. The portfolio is managed by an experienced team with deep sector expertise, aiming to maintain a balance across healthcare subsectors. Notable holdings typically include leading global healthcare companies such as Eli Lilly, UnitedHealth Group, and Novo Nordisk. The fund’s role is to provide investors with targeted exposure to innovation and structural growth within the life sciences and healthcare industries, making it a specialized option for sector-focused investing within the broader equity markets.
Performance
JNGLX had a total return of 21.90% in the past year, including dividends. Since the fund's inception, the average annual return has been 20.71%.
Top 10 Holdings
38.87% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 9.66% |
| Johnson & Johnson | JNJ | 5.59% |
| AstraZeneca PLC | AZN | 4.27% |
| UnitedHealth Group Incorporated | UNH | 3.44% |
| AbbVie Inc. | ABBV | 3.39% |
| Abbott Laboratories | ABT | 2.65% |
| argenx SE | ARGX | 2.63% |
| Novartis AG ADR | NVSN.MX | 2.50% |
| Praxis Precision Medicines, Inc. | PRAX | 2.39% |
| Boston Scientific Corporation | BSX | 2.35% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 5, 2025 | $3.69607 | Dec 5, 2025 |
| Dec 6, 2024 | $3.96273 | Dec 6, 2024 |
| Dec 7, 2023 | $2.94435 | Dec 7, 2023 |
| Dec 20, 2022 | $0.17114 | Dec 20, 2022 |
| Dec 20, 2021 | $6.81696 | Dec 20, 2021 |
| Dec 17, 2020 | $5.56759 | Dec 17, 2020 |